

**Suicidal ideations and attempts during a 12-month follow-up
in patients with obesity and MDD
(comparison between propensity-score matched cohorts)**

Population	Semaglutide cohort	Non-GLP-1RAs anti-obesity medications cohort	HR (95% CI)
Overall (n = 6,712/cohort)	1.6% (109)	2.3% (152)	0.73 (0.57–0.93)
Women (n = 4,962/cohort)	1.5% (73)	1.9% (95)	0.79 (0.58–1.07)
Men (n = 1,348/cohort)	1.9% (25)	3.0% (31)	0.62 (0.38–1.01)
age <= 45 years (n = 2,084/cohort)	2.8% (58)	3.5% (73)	0.82 (0.58–1.16)
age 46–64 years (n = 3,220/cohort)	1.1% (36)	1.6% (50)	0.73 (0.48–1.13)
age >=65 years (n = 1,404/cohort)	1.07% (15)	0.78% (11)	1.37 (0.63–2.99)
Black (n = 763/cohort)	<1.3% (<10)	3.0% (23)	0.44 (0.21–0.92)
White (n = 4,857/cohort)	1.6% (77)	2.1% (100)	0.79 (0.59–1.06)
No T2DM (n = 3,369/cohort)	1.2% (42)	2.0% (66)	0.66 (0.45–0.98)
T2DM (n = 3,271/cohort)	2.0% (66)	2.7% (87)	0.76 (0.55–1.05)

0.5 0.7 1.0 2.0
Hazard Ratio (HR)